A Case Series of Tofacitinib Treatment for Chronic Spontaneous Urticaria with Inadequate Response to Omalizumab
Tofacitinib shows potential in treating CSU patients with inadequate response to omalizumab, offering significant early symptom improvement in some cases with manageable safety. Larger randomized controlled trials are needed for further validation.
Authors
- Yujian Ye
- Xiaoyan Zhang
- Mengyan Zhu
Institutions
- Third People's Hospital of Hangzhou (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Clinical Cosmetic and Investigational Dermatology
- Published
- 2026-02-01
- DOI
- https://doi.org/10.2147/ccid.s577418
- Primary Topic
- Urticaria and Related Conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Health Commission of the People's Republic of China